NEI Podcast (Neuroscience Education Institute)

In this CME episode, Dr. Andrew Cutler interviews Dr. Charles Vega about the challenges of identifying bipolar disorder in primary care and how to over come them. They also discuss strategies for initiating and managing pharmacological treatment long term in collaboration with patients and psychiatric specialists.

Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study.

Learning Objective: After completing this educational activity, you should be better able to:

• Identify the key symptoms and diagnostic criteria for bipolar disorder to accurately screen and diagnose patients presenting in primary care settings
• Describe strategies for initiating and managing pharmacological treatment of bipolar disorder, including appropriate use of mood stabilizers, antipsychotics, and monitoring for side effects and adherence
• Explain the role of the primary care provider in coordinating care for bipolar disorder patients, including providing psychoeducation, determining appropriate level of care, and collaborating with mental health specialists when needed

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-PrimCare

Credit Designations: The following are being offered for this activity:

• Physician: ACCME AMA PRA Category 1 Credits™
• NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
• Nurse: ANCC contact hours
• NEI designates this Enduring Material for a maximum of 0.75 ANCC contact hour
• Nurse Practitioner: ACCME AMA PRA Category 1 Credits™
• American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
• The content in this activity pertaining to pharmacology is worth 0.75 continuing education hour of pharmacotherapeutics.
• Pharmacy: ACPE application-based contact hours
• This internet enduring, knowledge-based activity has been approved for a maximum of 0.75 contact hour (.075 CEU).
• The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period.
• Physician Associate/Assistant: AAPA Category 1 CME credits
• NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 0.75 AAPA Category 1 credit. Approval is valid until September 03, 2027. PAs should only claim credit commensurate with the extent of their participation.
• Non-Physician Member of the Healthcare Team: Certificate of Participation
• NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity.
• Interprofessional Continuing Education: IPCE credit for learning and change
• This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Disclosures are from the original live presentation, unless otherwise noted.

Faculty Author / Presenter
Andrew J. Cutler, MD
Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY
Chief Medical Officer, Neuroscience Education Institute, Malvern, PA

Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics
Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda
Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences

Faculty Author / Presenter
Charles P. Vega, MD
Clinical Professor, School of Medicine, University of California - Irvine, Orange, CA

Consultant/Advisor: Boehringer Ingelheim, Exact Sciences

The remaining Planning Committee member(s), Content Editor(s), Peer Reviewer(s), and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, Samantha Joy, and Brielle Calleo.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me.

Accessibility Statement

Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com.

Support: This activity is supported solely by the provider, NEI.

In this exciting interview we ask Dr. Vahabzadeh about his role as chief medical officer at Brain Power and the exciting projects that they are developing to help patients with autism. We also discuss the use of digital information, apps, and devices to help accurately predict suicide risk. We conclude with a sneak peak of what lies on the horizon for mental health in the digital age! 

Stigma surrounding mental illness and its treatment can be pervasive and negatively impact the quality of life of patients suffering with mental health problems. What role do psychiatric healthcare providers play in addressing and combating mental illness stigma? How do cultural factors influence the perception of mental illness and stigma? What are the best strategies for reducing stigma related to mental illness?

Dawn I. Velligan, PhD is a Professor in the Department of Psychiatry, Chief of the Division of Community Recovery, Research and Training, and the Henry B. Dielmann Chair at the University of Texas Health Science Center in San Antonio, Texas. Dr. Velligan’s internationally recognized research program focuses on the development and testing of psychosocial treatments to improve medication interest, follow-through, and outcomes for people with schizophrenia. She developed cognitive adaptation training; a treatment designed to improve functional outcomes for people with serious mental illness. Dr. Velligan is an author of numerous publications in high impact journals and has received grant funding from the National Institutes of Health, The National Alliance for Research on Schizophrenia and Depression, industry, and private foundations.

In Part II of this interview with Dr. Rona Hu, we discuss the most effective ways of assessing and preventing violence in the healthcare setting. Learn how to protect yourself, how to cope with such experiences, and how to support one another in the aftermath. 

In this episode, we discuss depression-related cognitive impairment with Dr. Roger McIntyre. Learn about the difference between hot and cold cognition, along with how to identify depression-associated cognitive symptoms that could alter the effectiveness of the very treatment approaches used for depression. Learn more about the relationship between bouts of depression and cognitive impairment and how to address this in your practice.

Dr. Roger McIntyre is a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is also Director for the Depression and Bipolar Support Alliance (DBSA) from Chicago, Illinois, USA. Dr. McIntyre is also Professor and Nanshan Scholar at Guangzhou Medical University, and Adjunct Professor College of Medicine at Korea University. Dr. McIntyre was named by Clarivate Analytics/Thomson Reuters in 2014, 2015, 2016, 2017 and 2018 as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade.

Healthcare disparities occur around the world, due to a complex, multifaceted situation that results from socioeconomic hardships, psychosocial stress, and cultural differences. In the United States, these disparities are often seen in minority communities, such as Hispanics and Black Americans. When a pandemic, such as COVID-19 occurs, it can expose these disparities in the most tragic ways. Current statistics surrounding healthcare disparities during the pandemic are staggering, suggesting that COVID-19 has disproportionately impacted the Black American community. In this important and timely interview with Dr. Napoleon Higgins, we address your most pressing questions on why this is occurring, and how awareness can improve this situation for future generations.

Dr. Napoleon Higgins, Jr., is a psychiatrist in the Houston/Clear Lake City Area. He currently serves as Owner, CEO and President of Bay Pointe Behavioral Health Service, Inc., and South East Houston Research Group, Inc. He also practices as the Medical Director of Hold My Hand Residential Treatment Center. Dr. Higgins specializes in treating mental health disorders through medication management, psychotherapy and behavioral training.

In this engaging interview, we ask Dr. Nora Volkow what common misconceptions exist that can influence the way clinicians treat pain and manage opioid addiction. We also ask her what risk factors are associated with opioid addiction and what early warning signs exist that a patient is becoming addicted. She also shares with us the most effective pain biomarkers available today, and in development so that we may be able to more effectively manage pain and avoid some of the risk associated with opioid treatment for pain. 

In today’s CME episode, Dr. Andrew Cutler will be interviewing Dr. Leslie Citrome about the safety and efficacy of VMAT2 inhibitors for the treatment of tardive dyskinesia.

Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD03

Learning Objectives: After completing this educational activity, you should be better able to:

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.

Credit Types. The following are being offered for this activity:

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented.

Interviewer
Andrew J. Cutler, MD
Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY
Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA
Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva
Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva

Interviewee
Leslie Citrome, MD, MPH
Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY
Consultant/Advisor: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona
Speakers Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, Teva
Stockholder: Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer, Reviva (options)

Pre-Interview Author
Sabrina K. Bradbury-Segal, PhD
Medical Writer, Neuroscience Education Institute, Carlsbad, CA
No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency and strategies for understanding and reducing the impact of implicit bias can be found in this handout.

Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences.

Released: July 27, 2022     CME/CE credit expires: July 27, 2025

In this excerpt, taken from his  presentation on the mental health consequences of COVID-19 for 2020NEIMax!, Dr. Sauve' addresses the rise in substance use disorders, and domestic violence as a result of the 2020 pandemic. 

Dr. William M. Sauvé received his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, and completed his residency in adult psychiatry at the National Capitol Consortium in Washington, DC, prior to deploying to the Al Anbar Province, Iraq, as the Regimental Psychiatrist for the 7th Marines.

After eleven years of active duty service, Dr. Sauvé left the United States Navy to become the Clinical Director of the Military Program at Poplar Springs Hospital in Petersburg, VA, an inpatient structured program for the treatment of Posttraumatic Stress Disorder and Chemical Dependency that caters exclusively to the military population. In 2014, he left Poplar Springs Hospital to focus on Transcranial Magnetic Stimulation and now serves as the Regional Medical Director, Virginia; Greenbrook TMS NeuroHealth Centers and the Medical Director for TMS NeuroHealth Centers in Richmond (Glen Allen) and Charlottesville, VA. Dr. Sauvé also consults for pharmaceutical companies and associated industries as well.

He is a member of the American Psychiatric Association, and certified by the American Board of Psychiatry and Neurology. Dr. Sauvé also recently co-authored “Psychopharmacological Treatment,” with Dr. Stahl, a chapter in Treating PTSD in Military Personnel, edited by Bret Moore and Walter Penk.

Opioid addiction, abuse, and overdose have all grown to epidemic proportions in the United States as well as worldwide in recent years—such information is no longer up for debate. With an estimated 400,000 persons using illicit opiates each month, and another 4 million reporting use of prescription pain relievers for nonmedical purposes, in the United States alone, the debate now surrounds how best to treat those individuals suffering from opioid use disorder (OUD). In the past few years, there has been growing evidence for the efficacy of medication assisted therapy (MAT) for the treatment of OUD. However, there are still many challenges. Questions arise such as: What sort of training does a prescriber need to undertake in order to be able to prescribe medications for the treatment of OUD and how is this a barrier to treatment? How are the billing procedures for MAT challenging for clinicians who are prescribing? In this CME NEI Podcast, Dr. Larissa Mooney answers these questions and more on MAT for OUD.

Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE.

Learning Objectives: After completing this educational activity, you should be better able to:

• Describe the challenges to treating opioid use disorder (OUD) with medication assisted therapy (MAT)
• Explore treatments designed to optimize cessation of opioid addiction
• Discuss legal barriers and insurance barriers to treatment of OUD

 Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MDs and DOs: NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.

Nurses and Physician Assistants: the ANCC and NCCPA accept organizations accredited by the ACCME as “providers of formally approved continuing education hours” (ANCC) and “Category 1 CME” (NCCPA). The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics.

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.

Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.

Faculty Interviewer / Author

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris

Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva

Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

Faculty Interviewer / Author

Larissa J. Mooney, MD

Associate Clinical Professor, Department of Psychiatry and Biobehavioral Sciences; Director, Addiction Medicine Clinic; University of California, Los Angeles Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA
Chief, Substance Use Disorders Clinic, VA Greater Los Angeles Healthcare System, Los Angeles, CA

No financial relationships to disclose.

Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

 Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

 Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.

 Support: This activity is supported by an unrestricted educational grant from Alkermes.

 Released: Sept 30, 2020          CME credit expires: Sept 30, 2023

Need to fulfill your CME credits? Join us virtually at NEI Max! and earn up to 28.75 CME credits. Check out with promo code PODCAST09 to get 10% off.

What are some mental health challenges for Asian Americans today? Can you share your thoughts on the most recent acts of violence against Asian Americans and where it comes from? In this timely and important episode, we interview Dr. Rona Hu on mental health in the Asian American community.

Dr. Hu is Medical Director of the Acute Psychiatric Inpatient Unit at Stanford Hospital, specializing in the care of those with serious mental illnesses, including schizophrenia, bipolar and depression. She completed medical school and residency in psychiatry at the University of California, San Francisco, and fellowships in Pharmacology and Schizophrenia Research through the National Institutes of Health. She is also active in  minority issues and cultural psychiatry, and has received regional and national recognition for her clinical care, research and teaching.

Dr. Rona J. Hu received her medical degree in 1990 from the University of California, San Francisco School of Medicine, and completed her residency at the University of California, San Francisco Medical Center in 1994. She received her board certification in psychiatry in 1995 from the American Board of Psychiatry and Neurology.

Dr. Hu completed two fellowships while at the National Institutes of Health (NIH) from 1994-1998. She completed the PRAT (Pharmacology Research Associate Training) program from 1994-1996, and a schizophrenia research fellowship from 1996-1998.

Dr. Hu received the 2016 APA Nancy Roeske award for Excellence in Medical Student Education, the 2017 Faculty Award from Stanford University's Asian American Activities Center, and the 2017 Community Engagement Award from Stanford Department of Psychiatry.

In this episode, Dr. David Goodman addresses your unanswered questions from his presentation, Setting the Mood: Strategies for Diagnosing and Treating ADHD in the Context of Bipolar Disorder, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this episode, Dr. David Goodman addresses your unanswered questions from his presentation: ADHD, Female Hormones, and Menopause: The Little We Know from Research at the 2022 NEI Synapse.

Dr. Napoleon B. Higgins, Jr. is a psychiatrist in the Houston/Clear Lake City Area. He is also CEO and President of Bay Pointe Behavioral Health Service, Inc., and South East Houston Research Group, Inc. He also practices as the Medical Director of Hold My Hand Residential Treatment Center.

Dr. Higgins has worked with and founded many programs that help to direct inner city young men and women to aspire to go to college and finish their educational goals. He has worked with countless community mentoring programs and has special interest in trauma, racism, and inner city issues and how they affect minority and disadvantaged children.

His books can be found at Amazon: 

"Mind Matters: A Resource Guide to Psychiatry for Black Communities”:

(https://www.amazon.com/dp/1979510687/ref=cm_sw_em_r_mt_dp_U_ZBahDb46SRHSH), 

“How Amari Learned to Love School Again”:

(https://www.amazon.com/dp/0997260564/ref=cm_sw_em_r_mt_dp_U_kDahDbTNM7KJJ)

"Transition to Practice: 21 Things Every Doctor Must Know in Contract Negotiations and the Job Search" (kindle or paperback direct from Amazon)

What are the risk factors for pediatric anxiety, and how might those be altered by the pandemic? How can emotional intelligence and emotion regulation play a role in managing anxiety? What is self-efficacy, and why is it so important for managing pediatric anxiety? In this timely episode, we discuss how to manage pediatric anxiety with Dr. Krystal Lewis.

Dr. Lewis is clinical psychologist with the Section on Development and Affective Neuroscience (SDAN) at the National Institute of Mental Health (NIMH). She is also a member of the Stigma Scientific Interest Group (SIG), and the NIMH Anti-Racism Task Force at the National Institute of Health (NIH). She specializes in cognitive behavioral therapy (CBT) for treating pediatric anxiety, and her research has focused on identifying mechanisms underlying the effectiveness of CBT. Dr. Lewis has extensive clinical experience treating anxious children and adolescents. She is also an advocate for early intervention, prevention and evidence-based treatments. She is currently a member of the Board for the Anxiety and Depression Association of America and co-chairs the Child and Adolescent Anxiety Special Interest Group.

Resources

Research Involvement at the NIMH: www.nimh.nih.gov/research

Clinical Studies at the NIMH: clinicalstudies.info.nih.gov

Clinical Study on Pediatric Anxiety: https://www.nimh.nih.gov/research/research-conducted-at-nimh/join-a-study/trials/childrens-studies/pediatric-mood-and-anxiety-research.shtml Call: (301) 827-1340 /Email: kidswithworries@mail.nih.gov

Websites

My Mental Health: Do I Need Help? (NIMH)

5 Things You Should Know About Stress (NIMH)

COVID-19: Stress and Coping (CDC)

Anxiety and Depression Association of America: https://adaa.org/

Books for children/adolescents

Outsmarting Worry: The Older Kids’ Guide to Managing Anxiety:

https://www.amazon.com/Outsmarting-Worry-Older-Managing-Anxiety/dp/1785927825/ref=sr_1_1?dchild=1&keywords=outsmarting+worry&qid=1613673934&s=books&sr=1-1

Rewire Your Anxious Brain For Teens: https://www.amazon.com/Rewire-Your-Anxious-Brain-Teens/dp/1684033764/ref=sr_1_3?dchild=1&keywords=rewire+your+anxious+brain+for+teens&qid=1613674062&s=books&sr=1-3

https://www.amazon.com/Teen-Girls-Anxiety-Survival-Guide/dp/1684035848/ref=sr_1_3?dchild=1&keywords=the+teens+girls+anxiety+survival+guide&qid=1613677471&s=books&sr=1-3#customerReviews

Books for Parents :

https://www.amazon.com/Helping-Anxious-Child-Step-Step/dp/1572245751/ref=sr_1_1?dchild=1&keywords=helping+your+anxious+child&qid=1613674245&s=books&sr=1-1

https://www.amazon.com/You-Your-Anxious-Child-Worries/dp/1583334955/ref=sr_1_1?dchild=1&keywords=anne+marie+albano&qid=1613677395&s=books&sr=1-1

https://www.amazon.com/Anxious-Kids-Parents-Courageous-Independent/dp/0757317626/ref=sr_1_3?crid=VR7NZWB285S2&dchild=1&keywords=anxious+parents+anxious+kids&qid=1613677372&s=books&sprefix=anxious+parents+%2Cstripbooks%2C167&sr=1-3

In this extended Q&A session with Dr. Andrew Cutler, we discuss your most important questions from his presentation on antipsychotic treatment approaches beyond the D2 receptor!

What led you to pursue a career in auditory neuroscience and what is the mission behind your laboratory, Brainvolts? What is the effect of bilingualism on Alzheimer’s disease? How can sound be used for the assessment of traumatic brain injury and other neurological conditions? In this episode, Dr. Nina Kraus addresses these questions and much more about the clinical applications for auditory neuroscience research. Her laboratory at Northwestern University, Brainvolts has discovered how to measure the biology of auditory processing with unprecedented precision. The implications of the research conducted there extends beyond the laboratory to schools, community centers, and clinics.

Nina Kraus, Ph.D. is a professor at Northwestern University who studies the biology of auditory learning. Through a series of innovative studies involving thousands of research participants from birth to age 90, her research has found that our lives in sound, for better (musicians, bilinguals) or worse (language disorders, concussion, aging, hearing loss), shape auditory processing. She continues to conduct parallel experiments in animal models to elucidate the mechanisms underlying these phenomena.

Never having accepted a lack of technology as a roadblock to scientific discovery, Kraus has invented new ways to measure the biology of sound processing in humans that provide precision and granularity in indexing brain function. With her technological innovations she is now pushing science beyond the traditional laboratory by conducting studies in schools, community centers, and clinics.

Using the principles of neuroscience to improve human communication, she advocates for best practices in education, health, and social policy. Dr. Kraus is the author of the book “Of Sound Mind: How our Brain Constructs a Meaningful Sonic World”.

Resources:

Link to “Of Sound Mind: How our Brain Constructs a Meaningful Sonic World”: https://www.amazon.com/Sound-Mind-Brain-Constructs-Meaningful/dp/0262045869#:~:text=Of%20Sound%20Mind%3A%20How%20Our,9780262045865%3A%20Amazon.com%3A%20Books

Link to Brainvolts: https://brainvolts.northwestern.edu/about-us/

Link to BEAMS hypothesis: https://brainvolts.northwestern.edu/wp-content/uploads/2021/07/Kraus_BEAMS_2021-1.pdf

Description: What is an Enhanced Treatment Program or ETP? What is the history behind it and how is it used today?

In this episode, Dr. Andrew Cutler interviews Dr. Carolina Klein about how to diagnose and treat antisocial personality disorder.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: Decriminalizing Mental Illness with Dr. Katherine Warburton

Part 2: The Antisocial Personality Disorder Spectrum: Diagnosis and Treatment with Dr. James Knoll

Part 3: Intensive Level Care for Violent Patients with Serious Mental Illness with Dr. Carolina Klein

Subscribe to the NEI Podcast, so that you don’t miss another episode!

What made you both want to write the book “Management of Complex Treatment-Resistant Psychotic Disorders? What are some of the most challenging components to treat, when it comes to complex psychosis and how are these addressed in the book?

In this episode, Dr. Andrew Cutler interviews Dr. Michael Cummings on how to manage complex treatment-resistant psychotic disorder.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: Management of Complex Treatment-Resistant Psychotic Disorders with Dr. Michael Cummings

Part 2: The Clozapine Handbook with Dr. Jonathan Meyer

Part 3: Don’t Guess! Measure: The Clinical Use of Antipsychotic Plasma Levels with Dr. Jonathan Meyer

Subscribe to the NEI Podcast, so that you don’t miss another episode!

What has research demonstrated about the advantages and consequences of telehealth for the treatment of ADHD and mental health? How can we fill the gaps in underserved communities when it comes to telehealth treatment for ADHD?

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on novel perspectives and novel treatment approaches for Attention Deficit Hyperactivity Disorder (ADHD).

Today, Dr. Andy Cutler interviews Dr. Greg Mattingly on best practices and guidelines for using telemedicine for the treatment and management of ADHD.

Let’s listen in to Part 2 of our theme: The Challenges of Treating ADHD Online

Subscribe to the NEI Podcast, so that you don’t miss another episode!

The first theme is on psychedelic assisted psychotherapy as a novel approach to the treatment of psychiatric disorders. Episodes to be released under this theme include:

Part 1: Now You See It, Now You Don’t: The Power of Psychedelic-Assisted Psychotherapy

Part 2: Forgetting to Be Addicted: Altering Compulsivity in the Addiction Process

Part 3: Forgetting Your PTSD: Using Reconsolidation to Forget Traumatic Memories

Subscribe to the NEI Podcast, so that you don’t miss another episode!

What was your experience like as co-chair of the Revision Subcommittee and DSM-5-TR editor? How was the impact of racism and discrimination on the diagnosis and manifestations of mental disorders addressed?

In this important and timely episode, Dr. Michael First addresses these questions and much more about the upcoming release of the DSM-5-TR in March 2022.

Dr. Michael B. First is a Professor of Clinical Psychiatry at Columbia University and a Research Psychiatrist at the Biometrics Department at the New York State Psychiatric Institute. He maintains a schematherapy and psychopharmacology practice in Manhattan. Dr. First is a nationally and internationally recognized expert on psychiatric diagnosis and assessment issues and has conducted expert forensic psychiatric evaluations in both civil and criminal matters, including the 2006 trial of the 9/11 terrorist Zacarias Moussaoui.

Dr. First is the Editorial and Coding Consultant for the DSM-5, the chief technical and editorial consultant on the World Health Organization's ICD-11 revision project and is an external consultant to the NIMH Research Domain Criteria project.

Dr. First has an undergraduate degree in Electrical Engineering and Computer Science from Princeton University, received a Masters in Computer Science and a Medical Degree from the University of Pittsburgh, completed his psychiatry residency at Columbia University, and also completed a fellowship in Biometrics Research under the direction of his mentor, Dr. Robert Spitzer.

He was the Editor of the DSM-IV-TR, the Editor of Text and Criteria for DSM-IV and the American Psychiatric Association (APA)'s Handbook on Psychiatric Measures. He has co-authored and co-edited a number of books, including A Research Agenda for DSM-V, the DSM-IV-TR Guidebook, the DSM-5 Handbook for Differential Diagnosis, and the Structured Clinical Interview for DSM-5 (SCID-5).

Notably, he is also the co-chair of the Revision Subcommittee and Editor of the DSM-5-TR

How can someone tell whether they are experiencing chronic levels of stress? The holidays are typically a great source of stress for most people. What are the unique challenges that we face this year in terms of the holidays during a pandemic? In this timely interview, Dr. Jennifer Love addresses these important questions, and so much more in this episode. With the release of her upcoming book, “When Crisis Strikes” she shares some powerful tips on detecting and managing chronic stress.

Dr. Jennifer Love is board-certified in psychiatry, addiction psychiatry and addiction medicine, and is a Diplomate of the American Board of Psychiatry and Neurology and the American Board of Addiction Medicine. She practices at a large clinic in Southern California. Dr. Love is an award-winning researcher and international speaker, interested in the interface between cultural and spiritual factors and overall mental health. Dr. Love’s work focuses on restoring life balance, brain and body health, and helping her patients improve their functionality and satisfaction in life. She considers a wide range of interventions including nutraceuticals, medication, exercise, yoga, psychotherapy, and sleep/relaxation training. Her specialties include: mood disorders, substance-use disorders, anxiety disorders, anger and irritability, behavioral addictions, co-occurring pain and opioid dependence.

Dr. Love is the co-author of When Crisis Strikes: 5 Steps to Heal Your Brain, Body, and Life from Chronic Stress. Stay up to date by following @dr_author_jennifer_love on Instagram.

Join us for this exciting extended Q&A session where Dr. Timothy Wilens addresses your most pressing questions from his presentation on transitioning from adolescence to adulthood with ADHD!

In this CME episode, Drs. Andrew Cutler and Roger McIntyre discuss the challenges and importance of diagnosing bipolar disorder as early as possible in the course of the illness. They also review strategies to achieve a correct diagnosis to provide the most efficacious and tolerable treatments available for bipolar disorder.

Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study.

Learning Objectives: After completing this educational activity, you should be better able to:

• Employ effective screening tools and assessment strategies to enhance diagnostic accuracy and achieve early diagnosis of bipolar disorder
• Develop patient-centered treatment plans that incorporate current evidence and individual patient factors
• Utilize shared decision-making approaches to optimize treatment outcomes for patients with bipolar disorder

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.

  Estimated Time to Complete: 1 hour

Released: November 01, 2024*   Expiration: October 31, 2027

*NEI maintains a record of participation for six (6) years.

CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-BD

Credit Designations: The following are being offered for this activity:

• Physician: ACCME AMA PRA Category 1 Credits™
• NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
• Nurse: ANCC contact hours
• NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour
• Nurse Practitioner: ACCME AMA PRA Category 1 Credit™
• American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
• The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics.
• Pharmacy: ACPE application-based contact hours
• This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU).
• The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period.
• Physician Associate/Assistant: AAPA Category 1 CME credits
• NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 31, 2027. PAs should only claim credit commensurate with the extent of their participation.
• Psychology: APA CE credits
• Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.
• Social Work: ASWB-ACE CE credits
• As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits.
• Non-Physician Member of the Healthcare Team: Certificate of Participation
• NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity.
• Interprofessional Continuing Education: IPCE credit for learning and change
• This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.

Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships.

Faculty Author / Presenter
Andrew J. Cutler, MD
Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, New York
Chief Medical Officer, Neuroscience Education Institute, Malvern, Pennsylvania
Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics
Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda
Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences

Faculty Author / Presenter
Roger S. McIntyre, MD, FRCPC
Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, Ontario, Canada
CEO, Braxia Scientific Corp, Toronto, Ontario, Canada
Grant/Research: Canadian Institutes of Health Research, China National Natural Research Foundation, Global Alliance for Chronic Diseases, Milken Institute
Consultant/Advisor: Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris

The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O’Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me.

Accessibility Statement

Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com.

Support: This activity is supported by an unrestricted educational grant from Alkermes, Inc.

In this episode, Dr. Mary Moller addresses questions about a wellness approach to treating Post-Traumatic Stress Disorder (PTSD). 

Dr. Mary D. Moller is an internationally known psychiatric mental health nurse clinician, researcher, educator, and presenter. She is an advanced registered nurse practitioner who is dually certified as a clinical specialist in adult psychiatric-mental health nursing and a psychiatric rehabilitation practitioner. She is an Associate Professor at Pacific Lutheran University in Tacoma, WA where she is coordinator of the psychiatric nurse practitioner Doctor of Nursing Practice program. She is also the Director of Psychiatric Services for Northwest Center for Integrated Health in Tacoma.

For access to the Wellness Assessment Tool click HERE.

Join us for this exciting extended Q&A session with Dr. Kari Franson, as she addresses your questions from her presentation on the legislation and legalization of marijuana and protecting your patients!

Join us in this episode with Dr. Cutler as he addresses some fascinating questions about his presentation on the most current findings on how to recognize and manage tardive dyskinesia!

What are some of the new FDA approvals for medications that happened this year? What did we learn about the association between ADHD and Alzheimer’s disease from a nationwide cohort study that was conducted? In this important and timely episode, Dr. Andrew Cutler addresses these questions and many more on the most interesting updates in psychopharmacology in 2021.

Dr. Andrew Cutler is the Chief Medical Officer (CEO) at the Neuroscience Education Institute (NEI). Dr. Cutler has deeply rooted knowledge in clinical experience, academic experience, and emerging science in psychiatry through clinical trials. He also worked closely with federal regulators and legislators to advocate for improved mental health care as part of the Clinton health care reform effort, leading to the Mental Health Parity Act of 1996.

Among his notable leadership positions, Dr. Cutler is currently Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University and previously served as Courtesy Assistant Professor of Psychiatry at University of Florida, and has been the principal investigator on more than 400 psychiatric and medical clinical trials.

Dr. Cutler received a BS in biology from Haverford College in Philadelphia, and then received his medical degree from the University of Virginia School of Medicine, where he was elected to Alpha Omega Alpha honor medical society. He completed his medical internship, internal medicine residency, and psychiatry residency at the University of Virginia, where he served as Chief Resident of Psychiatric Medicine. Dr. Cutler then served as Assistant Professor and Director of Psychiatric Medicine at the University of Chicago. He is board certified in internal medicine and psychiatry.

Resources:

This Month in Psychopharmacology: https://www.neiglobal.com/Members/MonthInPsychopharmNew/tabid/508/Default.aspx

FDA Clears Technology to Aid in Concussion Diagnosis: https://www.neiglobal.com/Members/MonthInPsychopharmPost/tabid/509/Default.aspx?topic=20527

International League Against Epilepsy Society (AES): https://www.ilae.org/

In this episode, we dive into a topic that is not talked about enough, yet many clinicians experience assault by patients. Here, we address how to identify risks, how to decrease escalation from agitation to aggression, and how to cope after a violent event has occurred with a patient.
Dr. Rona Hu is the Associate Dean of Academic Affairs at Stanford University School of Medicine. She is a Clinical Professor at Stanford University, and she was the formal Medical Director of the Acute Psychiatric Unit at Stanford for 20 years.

In this episode, join Dr. Robb while see addresses some of your most pressing questions about her presentation at Synapse on pediatric mood disorders! 

As we continue our stimulating discussion of Mental Wellness Month, we interview Dr. Gary Small on how to maintain brain health as we age! 

Dr. Gary Small is a Longevity Lifestyle Geriatric psychiatrist and director of the UCLA Longevity Center. He is also a professor in Psychiatry and Behavioral Sciences. Dr. Small has been named one of the world’s leading innovators in science and technology by Scientific American magazine, and his research, supported by the National Institutes of Health, has made headlines in TheWall Street Journal, The New York Times, and USA Today. He is known for his ability to both entertain and teach. 

Dr. Small has published several books on how to maintain brain health as we age and how to stay committed to mental wellness. You can find his books here at: http://drgarysmall.com/books/

What is the difference between mediators and moderators, and how do they influence treatment response? Why is it so important, as clinicians to understand the distinction between moderators and mediators and to be aware of their influence on treatment outcomes in the literature?

 In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Joseph Goldberg about their recent book, Practical Psychopharmacology: Translating Findings From Evidence-Based Trials Into Real-World Clinical Practice. Learn more about how moderators and mediators influence clinical outcomes.

Joseph F. Goldberg, MD, is a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particularly bipolar disorder and other forms of depression. He is a Clinical Professor in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai, New York, NY. He has spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine. Presently, he supervises and teaches psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintains a private practice in Norwalk, CT. His goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient. He has published over 180 original research publications in major psychiatric journals as well as several books on topics related to mood disorders. He serves on the board of directors of the American Society for Clinical Psychopharmacology and has lectured nationally and internationally at major scientific meetings and conferences.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: Placebo and Nocebo Effects in Psychopharmacology with Dr. Joseph Goldberg

Part 2: Mediators and Moderators in Psychopharmacology with Dr. Joseph Goldberg

Part 3: Interpreting the Literature in Psychopharmacology with Dr. Joseph Goldberg

 https://www.amazon.com/Practical-Psychopharmacology-Translating-Evidence-Based-Real-World/dp/1108450741/ref=sr_1_2?dchild=1&keywords=goldberg+stahl&qid=1631810148&sr=8-2

What was your personal experience with Match Day? What has your personal experience been like being transgender and how has this impacted your professional track when it comes to clinicians treating patients who are nonbinary or transgender?

In this podcast episode, Dr. Mulkey addresses these questions and more about psychiatry residency and Match Day.

Dr. Nat Mulkey, MD is a psychiatrist and first-year resident at the University of Vermont Medical Center. They graduated from Boston University School of Medicine, where they worked closely with faculty on LGBTQI+ curricula in undergraduate medical education and related initiatives. Their interests include child and adolescent psychiatry, LGBTQI+ mental health, pharmacology, addiction, and first break psychosis. Their hobbies are creative writing and trail running. 

Articles by Nat Mulkey, MD:

The Search for a Cause of Transness Is Misguided - Scientific American

Misgendering in Medicine: How to Improve Care of Transgender and Gender Non-Binary Patients » in-Training, the online peer-reviewed publication for medical students

https://www.psychiatrictimes.com/view/mental-health-crisis-ground-level

https://www.aamc.org/news-insights/finding-my-community-gaymedtwitter

Resources for LGBTQ+ Clinicians and Caregivers:

Gender Spectrum Homepage - Gender Spectrum

Transgender Professional Association for Transgender Health | Trans Health by Trans People (tpathealth.org)

Education & Training - Fenway Health: Health Care Is A Right, Not A Privilege.

Resources for LGBTQ+ Patients: 

https://www.lgbtqiahealtheducation.org/resources/

https://www.uvmhealth.org/childrens-hospital/pediatric-specialties/transgender-youth-program/transgender-resources

https://www.uvm.edu/health/transhealth

In this episode, Dr. Manpreet Singh addresses your unanswered questions from her joint presentation, Don’t Get Mixed Up! Recognizing and Treating Mixed Features Across the Lifespan, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

Join Dr. Andy Cutler through this lightning-speed review of how to manage antipsychotic medications and treat psychosis. Tune in for the latest information from this year's Congress! 

What has research shown about the effectiveness of psychedelic or dissociative agents in the treatment of addiction? What is pharmacological extinction? What types of addictions have been researched, using this method as a treatment approach? In Part II of this special series, the PsychopharmaStahlogy Show Dr. Andrew Cutler asks Dr. Stephen Stahl these questions, and so much more!

Don’t miss Part III of this interview.  With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month.

The first theme is on psychedelic assisted psychotherapy as a novel approach to the treatment of psychiatric disorders. Episodes to be released under this theme include:

Part I: Now You See It, Now You Don’t: The Power of Psychedelic-Assisted Psychotherapy

Part II: Forgetting to Be Addicted: Altering Compulsivity in the Addiction Process

Part III: Forgetting Your PTSD: Using Reconsolidation to Forget Traumatic Memories

Subscribe to the NEI Podcast, so that you don’t miss another episode!

Join us in this episode, as Dr. Mago answers some important questions on his presentation about side effects that can lead to nonadherence!

In this episode we discuss how to manage the opioid crisis when it comes to patient care, from effective communication with patients, to the most novel treatments with Dr. Thomas Kosten. 

Dr. Kosten is the JH Waggoner Chair and Professor of Psychiatry, Pharmacology, Immunology and Neuroscience, Vice Chair for Psychiatry and Co-director of the Dan L. Duncan Institute for Clinical and Translational Research (ICTR) at Baylor College of Medicine. His pharmacotherapy research activities include a cocaine vaccine, disulfiram for cocaine dependence, vasodilators for cocaine-induced cerebral perfusion defects and buprenorphine for opioid dependence. In addition to these pharmacotherapies, he has advanced the understanding of opiate and cocaine dependence mechanisms and treatment using SPECT and functional MRI neuroimaging.

In this exciting extended Q&A session, Dr. William Sauve’ addresses some of your unanswered questions about his presentation on the current applications for the treatment of neuropsychiatric conditions with brain stimulation techniques!

How large of an issue is treatment non-adherence in the serious mental illness (SMI) population? How does therapeutic alliance influence treatment adherence? What are some effective strategies for improving medication adherence? Dr. Andrew Cutler interviews Dr. Peter Weiden to find answers to these questions and more!

Peter J. Weiden, MD is an internationally recognized expert in the treatment of schizophrenia and related psychotic disorders. Dr. Weiden has a distinguished career spanning academia, clinical trials, and industry. His academic career included positions as Professor of Psychiatry at SUNY Downstate Medical Center from 1999-2007 and at UIC Medical Center from 2007-2014. Dr. Weiden served as Chief Medical Officer for Uptown Research in Chicago and continued as clinical investigator of new and emerging treatments for schizophrenia. His industry experience includes joining Alkermes to focus on development of new treatments for schizophrenia, including the long-acting formulation aripiprazole lauroxil and the combination product olanzapine/samidorphan. He joined Karuna Therapeutics in 2020 to support development of the investigational muscarinic agonist xanomeline-trospium, currently in phase 3 development for the treatment of schizophrenia. This year, Dr. Weiden returned to clinical practice and provides consulting and educational services via PJWeiden, LLC. His areas of expertise include drug development, clinical trials, and clinician education.

Join us for Part II of this exciting interview with Dr. Napoleon Higgins Jr!

Dr. Napoleon B. Higgins, Jr. is a psychiatrist in the Houston/Clear Lake City Area. He is also CEO and President of Bay Pointe Behavioral Health Service, Inc., and South East Houston Research Group, Inc. He also practices as the Medical Director of Hold My Hand Residential Treatment Center.

Dr. Higgins has worked with and founded many programs that help to direct inner city young men and women to aspire to go to college and finish their educational goals. He has worked with countless community mentoring programs and has special interest in trauma, racism, and inner city issues and how they affect minority and disadvantaged children.

His books can be found at Amazon: 

"Mind Matters: A Resource Guide to Psychiatry for Black Communities”:

(https://www.amazon.com/dp/1979510687/ref=cm_sw_em_r_mt_dp_U_ZBahDb46SRHSH), 

“How Amari Learned to Love School Again”:

(https://www.amazon.com/dp/0997260564/ref=cm_sw_em_r_mt_dp_U_kDahDbTNM7KJJ)

"Transition to Practice: 21 Things Every Doctor Must Know in Contract Negotiations and the Job Search" (kindle or paperback direct from Amazon)

In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer on best practices and strategies for improving clinician and patient communication, medication adherence, and collaboration in the community when it comes to treating schizophrenia.

Optional CE Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CE credit, click https://nei.global/POD21-Schiz

Learning Objectives: After completing this educational activity, you should be better able to:

• Demonstrate strategies that involve patient and caregivers in shared informed decision-making for treatment goals
• Discuss the role of social aspects of community and behavioral health settings on patient experiences and treatment outcomes
• Address best practices for the use of telemedicine when monitoring treatment for schizophrenia and the use of LAIs

Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MDs and DOs: NEI designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CE credit.

Nurses and Physician Assistants: the ANCC and NCCPA accept organizations accredited by the ACCME as providers of “formally approved continuing education hours” (ANCC) and “Category 1 CME” (NCCPA). The content in this activity pertains to pharmacology and is worth 1.25 continuing education hours of pharmacotherapeutics.

Peer Review: The content was peer-reviewed by an MD specializing in forensic psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.

Interviewer

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA

Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva

Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

Interviewee

Jonathan M. Meyer, MD

Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA

Consultant/Advisor: Acadia, Alkermes, Intra-Cellular, Neurocrine

Speakers Bureau: Acadia, Alkermes, Intra-Cellular, Neurocrine, Noven, Otsuka, Sunovion, Teva

Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture

Support: This activity is supported by an unrestricted educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.

Released: September 23, 2021          CE credit expires: September 23, 2024

How can you tell the difference between postpartum blues and postpartum depression? Join us in this episode, as Dr. Marlene Freeman addresses questions like this about maternal mental health. 

Dr. Marlene Freeman is the Associate Director of the Center for Women’s Mental Health at Massachusetts General Hospital and the Medical Director of the MGH Clinical Trials Network and Institute (CTNI).Her research and clinical expertise is in the areas of mood disorders and women’s mental health. She also has had clinical and research interests in the areas of nutrition, integrative medicine, and mental health. She previously directed programs in women’s mental health at the University of Arizona College of Medicine and at UT-Southwestern in Dallas.

What unique risk factors surround the COVID-19 pandemic and potential heightened risk of suicide? What populations have been most vulnerable to mental health consequences, substance use disorders, suicidal ideation, and self-harm during the pandemic and why? In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl on the suicide risk and prevalence during this challenging time.

Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada.

Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade.

Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The second theme is treatment-resistant depression and suicide prevention.

Episodes to be released under this theme include:

Part 1: Treatment Resistant Depression and Suicide Prevention: Hot Off the Press Ketamine Guidelines with Dr. Roger McIntyre

Part 2: Shelter-In-Place During the Storm: Mental Health Consequences and Suicide Prevention During the COVID-19 Pandemic with Dr. Roger McIntyre

Part 3: Beyond the Storm: An Update on Suicide Prevention and The Suicide Prevention Handbook with Dr. Christine Moutier

Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this episode, Dr. Jonathan Meyer addresses your unanswered questions from his presentation: Dopamine Partial Agonists: How They Work and Why They Don’t Always Play Nice with Other Antipsychotics.

In this episode, Dr. Sarah Vinson addresses your unanswered questions from her panel presentation, Serious Mental Illness: A Collaborative Approach, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this re-release episode, Dr. Andrew Cutler interviews Drs. Marko Perko and Stephen Stahl about their book, Tesla: His Tremendous and Troubled Life, which explores the intersection between Tesla’s genius, his creativity, and his bipolar disorder. Sadly, Dr. Marko Perko passed away last fall after a battle with cancer. He was a prolific writer and a great mind, and we re-release this episode in his honor.

Learn more about Tesla: His Tremendous and Trouble Life

June is Postraumatic Stress Disorder (PTSD) Awareness Month! In this episode we interview Dr. John Liebert, an expert in military-related and civilian PTSD. 

Dr. Liebert is a psychiatrist in Scottsdale, Arizona. He received his medical degree from McGill University Faculty of Medicine and has been in practice for more than 20 years. His special interests include complex mood, impulse and anxiety disorders for both adult, child, and geriatric populations.  Dr Liebert is a graduate of The US Air Force School of Aerospace Medicine and served as a Flight Surgeon in charge of Human Reliability Program for transportation of nuclear warheads worldwide. 

 His book “Wounded Minds: Understanding and Solving the Growing Menace of Post-Traumatic Stress Disorder” can be found here: https://www.amazon.com/Wounded-Minds-Understanding-Post-Traumatic-Disorder/dp/1634502876

 His textbook: Psychiatric Criminology, which has a section on special problems of veterans in Chapter 9 can be found here: https://www.amazon.com/Psychiatric-Criminology-Roadmap-Rapid-Assessment/dp/149871417X 

In this episode, Dr. Adelaide Robb addresses your unanswered questions from her presentation: Assessment and Treatment of Pediatric Impulsive Aggression: A Transdiagnostic Issue.

In this re-release episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl about the dark side of neuroplasticity, or pathologic neuroplasticity, and what we may be able to do to combat it.

In this episode, Dr. Vladimir Maletic addresses your unanswered questions from his presentations, “From Despair to Delight: Advances in the Diagnosis and Treatment of Anhedonia” and “Ho Hum to Aha! Treating Anhedonia and Emotional Blunting.”

What is the proposed neurocircuitry that underlies attention deficit hyperactivity disorder, or ADHD? What is known about the role of serotonin in ADHD? Particularly the 5HT2C and 5HT7 receptors?

With this special series, brought to you by the NEI Podcast, we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on novel perspectives and novel treatment approaches for Attention Deficit Hyperactivity Disorder (ADHD).

Today, Dr. Andy Cutler interviews Dr. Stephen Stahl on the current state of ADHD and where the future lies.

Let’s listen in to Part 1 of our theme: Shifting Focus: A Novel Perspective on Attention Deficit Hyperactivity Disorder (ADHD)

Subscribe to the NEI Podcast, so that you don’t miss another episode!

Why is it so important that many Olympic athletes are speaking out about the importance of mental health, and how can people spread more awareness for mental health concerns in this vulnerable population? What challenges do you face regarding effectively treating mental health conditions in athletes? In this important and timely interview sports psychiatrist, Dr. Greg Mattingly addresses these questions and much more!

Dr. Mattingly is a physician and principal investigator in clinical trials for Midwest Research Group. He is also a founding partner of St. Charles Psychiatric Associates where he treats children, adolescents and adults. A St Louis native, he earned his medical degree and received a Fulbright scholarship while attending Washington University. Dr. Mattingly is board certified in adult and adolescent psychiatry and is a Diplomat of the National Board of Medical Examiners. He is an Associate Clinical Professor at Washington University. Dr. Mattingly has been a principal investigator in over 300 clinical trials focusing on ADHD, anxiety disorders, major depression, bipolar disorder and schizophrenia. Having served on numerous national and international advisory panels, Dr. Mattingly has received awards and distinctions for clinical leadership and neuroscience research. Dr. Mattingly currently serves on the board of directors for APSARD-The American Professional Society of ADHD and Related Disorders and is a certified evaluator for both the NFL and MLB. An avid runner and outdoorsman, Dr. Mattingly believes mind, body and spirit are important qualities for him and his family.

Resources: www.Midwestresearchgroup.com

When it comes to Alzheimer’s disease, what is the amyloid cascade hypothesis? How has this theory impacted drug development for Alzheimer’s disease over the past three decades?

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on Alzheimer’s disease, the amyloid hypothesis, disease modification, and breakthroughs in diagnosis and treatment.

Today, Dr. Andy Cutler interviews Dr. Stephen Stahl on the current state of Alzheimer’s disease and the amyloid controversy.

Let’s listen in to Part 1 of our theme: Alzheimer’s Disease and the Amyloid Controversy

Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this interview, Dr. Rajnish Mago discusses how to deal with the challenge of side effects when treating mental illness. 

What did we learn about the relationship between PTSD and the gut microbiome this year? What are pherines? How can they reduce anxiety, according to research that was published this year? What other exciting news about psychopharmacology do you have to share with us? In this episode, Dr. Cutler addresses these questions and so much more about this past year in psychopharmacology.

Dr. Andrew Cutler is the Chief Medical Officer (CEO) at the Neuroscience Education Institute (NEI). Dr. Cutler has deeply rooted knowledge in clinical experience, academic experience, and emerging science in psychiatry through clinical trials. He also worked closely with federal regulators and legislators to advocate for improved mental health care as part of the Clinton health care reform effort, leading to the Mental Health Parity Act of 1996.

Among his notable leadership positions, Dr. Cutler is currently Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University and previously served as Courtesy Assistant Professor of Psychiatry at University of Florida, and has been the principal investigator on more than 400 psychiatric and medical clinical trials.

Dr. Cutler received a BS in biology from Haverford College in Philadelphia, and then received his medical degree from the University of Virginia School of Medicine, where he was elected to Alpha Omega Alpha honor medical society. He completed his medical internship, internal medicine residency, and psychiatry residency at the University of Virginia, where he served as Chief Resident of Psychiatric Medicine. Dr. Cutler then served as Assistant Professor and Director of Psychiatric Medicine at the University of Chicago. He is board certified in internal medicine and psychiatry.

The 19th annual NEI Congress is upon us. Whether you’ve already secured your spot to join us in person at The Broadmoor in Colorado Springs or plan to attend virtually via simulcast OR are still unsure if this event is for you, you’re in luck. This is our Congress preview episode.

 Congress chairman, Dr. Andrew Cutler interviews a few of the brilliant faculty members who will be speaking at this year’s conference for a sneak peek of their presentations and finds out what they are looking forward to at the upcoming event.

Register now for 2023 NEI Congress at: https://nei.global/23cng-REG_neipod

Who is Pear and what are prescription digital therapeutics? Why are PDTs so important to the continuum of care, especially when it comes to mental health? In this fascinating interview, Dr. Andrew Cutler interviews Dr. Corey McMann, the President and CEO of Pear Therapeutics about the importance of this technology in treating mental health.

Corey M. McCann, MD, PhD, is the President and CEO of Pear Therapeutics. Previously, Corey was an investor with MPM Capital, where he evaluated new healthcare investment opportunities, managed relationships with strategic partners, and oversaw strategy and execution at portfolio companies. Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He led McKinsey’s central nervous system expertise group, advising clients across the healthcare value chain.

April is Autism Awareness Month! Join us, as we interview Dr. Arshya Vahabzadeh on the hallmark features of autism, and how to use digital technological advancements to effectively treat symptoms related to autism. 

Dr. Vahabzadeh is a family physician, having completed training under the Royal College of General Practitioners. Dr. Vahabzadeh is deeply interested in neurodevelopmental disorders, including autism and schizophrenia. He is also a leadership fellow of the American Psychiatric Association. He practices as a resident child and adolescent psychiatrist at Massachusetts General Hospital and McLean Hospital, in addition to being a clinical fellow at Harvard Medical School. His research experience has encompassed several lines of study, including genetics, novel psychopharmacology and social cognition. He is also Chief Medical Officer at Brain Power, a neurotechnology company with a wearable smart glass system for patients with autism. Dr. Vahabzadeh is also a strong proponent of mental health education, and has written editorials for Psychology Today, The Huffington Post, APA Healthy Minds, Boston Magazine and CNN.

May is Borderline Personality Disorder Awareness Month! Join us in this fascinating interview with Dr. Robert Gregory. Dr. Robert Gregory is Professor of Psychiatry and Behavioral Sciences at Upstate Medical University where he serves as Director of the Psychiatry High Risk Program, a treatment program for youth and young adults struggling with suicidal thoughts or behaviors.  Areas of interest and special expertise include borderline personality disorder, addictions, and suicide prevention.  He is the developer of one of the evidence-based treatments for borderline personality disorder, called Dynamic Deconstructive Psychotherapy.

In this CME episode, Dr. Andrew Cutler interviews Dr. Vladimir Maletic about novel agents in development for Major Depressive Disorder or MDD.

Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-MDD.

Learning Objectives: After completing this educational activity, you should be better able to:

• Describe novel mechanisms of action of agents under investigation for the treatment of depression
• Explain the potential implications of novel rapid-acting and multi-modal agents in optimizing outcomes for patients with unipolar depression
• Integrate newly available options for depression into clinical practice

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.

Credit Types. The following are being offered for this activity:

• Nurse Practitioner: ANCC contact hours
• Pharmacy: ACPE application-based contact hours
• Physician: ACCME AMA PRA Category 1 Credits ™
• Physician Assistant: AAPA Category 1 CME credits
• Psychology: APA CE credits
• Social Work: ASWB-ACE CE credits
• Non-Physician Member of the Mental Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any potential conflicts of interest were identified and mitigated prior to the activity being planned, developed, or presented.

Interviewer
Andrew J. Cutler, MD
Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY
Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA
Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva
Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva

Interviewee
Vladimir Maletic, MD, MS
Clinical Professor of Psychiatry, University of South Carolina School of Medicine, Greenville, SC
Consultant/Advisor: AbbVie, Alfasigma, Alkermes, Biogen/Sage, Intracellular, Ironshore, Janssen, Lundbeck, Otsuka, Relmada, Sunovion, Supernus, Takeda
Speakers Bureau: AbbVie, Alfasigma, Alkermes, Biogen/Sage, Intracellular, Ironshore, Janssen, Lundbeck, Otsuka, Sunovion, Supernus, Takeda

Pre-Interview Author
Sabrina K. Bradbury-Segal, PhD
Medical Writer, Neuroscience Education Institute, Carlsbad, CA
No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency and strategies for understanding and reducing the impact of implicit bias can be found in this handout.

Support: This activity is supported by an unrestricted educational grant from Sage Therapeutics, Inc.

Released: September 26, 2022     CME/CE credit expires: September 26, 2025

The years 2019-2020 brought to us coronavirus disease 2019 (COVID-19), resulting in an unprecedented global pandemic. Emerging data, historical studies, and expert opinion point to a tremendous impact of COVID-19 on the development and exacerbation of psychiatric issues. This issue is compounded by the fact that access to mental health care services may be limited during this time of crisis. There is a critical need for mental health care providers to be prepared and educated to best serve the psychiatric needs of patients affected, either directly or indirectly, by the COVID-19 pandemic. There are still many questions. What are the psychological consequences of so many people losing their jobs, and so many businesses shutting down? What are some healthy coping strategies for parents to model at home, to protect their children’s mental health during this pandemic? In this CME NEI podcast episode, Dr. McIntyre answers these questions, and much more.

 Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE.

 Learning Objectives: After completing this educational activity, you should be better able to:

• Discuss the psychological, economic, and sociological implications that COVID-19 has had on mental health
• Examine the impact of COVID-19 on a variety of mental health issues
• Explore existing and novel strategies for continuing mental health care during a global pandemic such as COVID-19

Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.

 Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Peer Review: The content was peer-reviewed by a PhD-PMHNP specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.

 Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.

 Faculty Interviewer / Author

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris

Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva

Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

Faculty Interviewee / Author

Roger S. McIntyre, MD, FRCPC  

Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada

Grant/Research: CIHR/GACD/Chinese National Natural Research Foundation, Stanley Medical Research Institute

Consultant/Advisor: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, Takeda

Speakers Bureau: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, Takeda

 Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

 The Planning Committee and Peer Reviewer have no financial relationships to disclose.

 Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

 Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.

 Support: This activity is supported by an unrestricted educational grant from Alkermes.

 Released: July 9, 2020          CME credit expires: July 9, 2023

Join us in this exciting debate about when side effects warrant medication change. Dr. Andrew Cutler and Dr. Roger McIntyre address some of the most important issues surrounding this topic. This podcast was recorded live at NEI's 2019 Synapse Conference in Asheville, North Carolina! 

In this episode, Dr. Andrew Cutler interviews Mr. Marko Perko and Dr. Stephen Stahl about their newly released book “Tesla: His Tremendous and Troubled Life” and the intersection between Tesla’s genius, creativity, and bipolar disorder. How is your book unique from any book that’s been written on Tesla before? What is the main message that you’d like readers to take away from this book? In this episode Mr. Perko and Dr. Stahl address these questions and much more!

Marko Perko is a graduate of the University of Southern California. He has always had an insatiable thirst for knowledge of all types, and as such, he is highly regarded as a modern-day Renaissance man, author, historian, polymath, polemicist, and history communicator. He is the author of the critically acclaimed and wildly popular book “Did You Know That . . .?” He is also a novelist and the writer of an international bestselling knowledge-based board game, as well as the creator of the Cultural Enrichment Programs education series, and a software developer―Krypti.com.

Perko has written for and edited numerous publications, and he has worked as a columnist, speechwriter, composer, musician, lecturer, and playwright. He is a member of The Authors Guild; the Biographers International Organization; the American Society of Composers, Authors and Publishers; Broadcast Music, Inc.; the Institution of Engineering and Technology; the British Library; and the Organization of American Historians.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: The Lightning in the Storm: Creativity in Bipolar Disorder

Part 2: Nikola Tesla’s Evil Twins: Genius and Madness with Marko Perko

Part 3: History of Creative Famous Individuals with Bipolar Disorder

Subscribe to the NEI Podcast, so that you don’t miss another episode!

Link to “Tesla: His Tremendous and Troubled Life”: https://www.amazon.com/Tesla-His-Tremendous-Troubled-Life-ebook/dp/B09QMPH6MG/ref=sr_1_1?crid=O0UAHNGC8Z0J&keywords=tesla+by+marko+perko&qid=1652729759&sprefix=tesla+by+marko+perko%2Caps%2C113&sr=8-1

In this episode, listen in for an extended Q&A session with Dr. Jeffrey Strawn as he answers your most pressing questions from his presentation on treating refractory anxiety disorders.

What is the prevalence of bipolar disorder in the pediatric population and does this change, depending on age? What are important tips for recognizing hypomania in children, and diagnosing children with mixed depression? In this episode, we address these questions and more with pediatric psychiatrist, Dr. Manpreet Singh. 

Dr. Singh is Associate Professor of Psychiatry and Behavioral Sciences at Stanford University, and leads a program aimed to accelerate understanding and treatment in youth with or at high risk for developing lifelong mood disorders. She is the director of the Pediatric Mood Disorders Program and the Pediatric Emotion and Resilience Program at Stanford University.

Dr. Singh earned her MD at Michigan State University and her MS at University of Michigan. She completed her combined residency training in Pediatrics, Psychiatry, and Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center. After two years of T32 postdoctoral training at Stanford’s Center for Interdisciplinary Brain Sciences Research, she joined the faculty in 2009.

Dr. Singh leads a multidisciplinary team that evaluates and treats youth with a spectrum of mood disorders as young as age 2 and well into their 20s. Her NIMH and industry funded studies examine mechanisms underlying mood disorders and apply cutting edge strategies to directly modulate the brain using transcranial magnetic stimulation and real time neurofeedback. She is also investigating the efficacy and safety of pharmacotherapies and psychotherapies, such as family focused psychotherapy and mindfulness meditation, to reduce mood symptoms and family stress. All of these areas of research aim to elucidate core mechanisms underlying mood disorders and how treatment early in life can pave the path to more adaptive outcomes.

In her spare time, Dr. Singh enjoys traveling and hiking with her husband and three children, and avidly teaches Indian classical music. Her clinical handbook for the diagnosis and treatment of pediatric mood disorders can be found at the link below:

https://appi.org/Products/Mood-Disorders/Clinical-Handbook-for-the-Diagnosis-and-Treatment?SearchText=clinical%20handboo&sku=37174

Tardive dyskinesia (TD) is a movement disorder characterized by involuntary movements of the tongue, lips, face, trunk, and extremities that occur in patients treated with dopamine receptor blocking agents (DRBAs). Patients can have symptoms that persist for months, years, or even permanently. Greater awareness about risk factors and which agents may be associated with higher likelihood of developing TD is critical to reduce the prevalence of this disorder. Understanding the most effective novel treatment approaches to TD is also important. In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the current best practices in the diagnosis, recognition, and treatment of tardive dyskinesia.

 Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-TD

 Learning Objectives: After completing this educational activity, you should be better able to:

• Identify the clinical presentation of tardive dyskinesia
• Implement treatment strategies for the management of tardive dyskinesia

 Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NEI designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.

 Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.50 continuing education hour of pharmacotherapeutics.

 Peer Review: The content was peer-reviewed by a PhD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.

 Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.

 Interviewer

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva

Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

 Interviewee

Jonathan M. Meyer, MD

Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA

Consultant/Advisor: Acadia, Alkermes, Allergan, Intra-Cellular Therapies, Neurocrine

Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Neurocrine, Otsuka, Sunovion, Teva

 Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

 The Planning Committee and Peer Reviewer have no relevant financial relationships to disclose.

 Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

 Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.

 Support: This activity is supported by an unrestricted educational grant from Neurocrine Continental, Inc.

 Released: November 19, 2020          CME credit expires: November19, 2023

In this episode, Dr. Mary Kimmel answers your important questions from her presentation: No Woman, No Cry: Advancements in the Diagnosis and Treatment of Postpartum Depression.

In what ways do we have the power to influence neuroplasticity? How would you define pathologic or dark neuroplasticity? Are there ways to enhance or preserve our circuits as a form of adaptive neuroplasticity?

In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl on dark neuroplasticity.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: The Power of Dark Persuasion with Dr. Joel Dimsdale

Part 2: Dark Psychiatry and Social Media with Dr. Donatella Marazziti

Part 3: Good and Bad Neuroplasticity

Subscribe to the NEI Podcast, so that you don’t miss another episode!

Why do you feel that when it comes to psychopharmacology, knowing how to really interpret the scientific literature is important for clinicians? Why is it important to know whether the clinical characteristics of the subjects resemble or differ from your own patients and to what extent?

 In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Joseph Goldberg about their recent book, Practical Psychopharmacology: Translating Findings From Evidence-Based Trials Into Real-World Clinical Practice. Learn more about why it is important to understand how to interpret the scientific literature and apply it to your clinical practice.

Joseph F. Goldberg, MD, is a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particularly bipolar disorder and other forms of depression. He is a Clinical Professor in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai, New York, NY. He has spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine. Presently, he supervises and teaches psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintains a private practice in Norwalk, CT. His goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient. He has published over 180 original research publications in major psychiatric journals as well as several books on topics related to mood disorders. He serves on the board of directors of the American Society for Clinical Psychopharmacology and has lectured nationally and internationally at major scientific meetings and conferences.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: Placebo and Nocebo Effects in Psychopharmacology with Dr. Joseph Goldberg

Part 2: Mediators and Moderators in Psychopharmacology with Dr. Joseph Goldberg

Part 3: Interpreting the Literature in Psychopharmacology with Dr. Joseph Goldberg

https://www.amazon.com/Practical-Psychopharmacology-Translating-Evidence-Based-Real-World/dp/1108450741/ref=sr_1_2?dchild=1&keywords=goldberg+stahl&qid=1631810148&sr=8-2

What is the evidence that exercise is at least as effective as medications for the treatment of mental health disorders, such as depression? Can you share any research findings on the effects of exercise for patients with traumatic brain injury?  If you have questions like these, you won't want to miss this episode with psychiatrist and renowed author, Dr. John Ratey!

Best selling author, John J. Ratey, MD, is an Associate Clinical Professor of Psychiatry at Harvard Medical School and an internationally recognized expert in Neuropsychiatry. He has published over 60 peer-reviewed articles, and 11 books published in 17 languages, including the groundbreaking ADD-ADHD “Driven to Distraction” series with Ned Hallowell, MD. With the publication of  "Spark-The Revolutionary New Science of Exercise and the Brain," Dr. Ratey has established himself as one of the world's foremost authorities on the brain-fitness connection.  His most recent book, “Go Wild” explores how we can achieve optimal physical and mental health by getting in touch with our caveman roots, and how we can “re-wild” our lives.

  Recognized by his peers as one of the Best Doctors in America since 1997, Dr. Ratey was recently honored by the Massachusetts Psychiatric Society as "Outstanding Psychiatrist of the Year" for advancing the field. Dr. Ratey and his work are frequently profiled in the media, where he’s been featured on ABC, CBS, NBC, PBS and NPR, as well as in The New York Times, Newsweek, The Washington Post, US News and World Report, Men’s Health, and other national publications.

Why is measurement-based care so important to the overall treatment of schizophrenia? What are the most important reasons for using plasma antipsychotic levels when treating schizophrenia patients?  

In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the importance of measuring plasma levels when administering antipsychotics.  

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on complex treatment-resistant psychotic disorders. 

Episodes to be released under this theme include: 

• Part 1: Management of Complex Treatment-Resistant Psychotic Disorders with Dr. Michael Cummings 
• Part 2: The Clozapine Handbook with Dr. Jonathan Meyer 
• Part 3: Don’t Guess! Measure: The Clinical Use of Antipsychotic Plasma Levels with Dr. Jonathan Meyer 

Subscribe to the NEI Podcast, so that you don’t miss another episode! 

In this episode, we raise awareness about a forgotten, yet extremely vulnerable population at high risk for traumatic brain injury (TBI). What are ways that we can better screen for patients who have experienced intimate partner violence (IPV)? How are types of brain injuries unique in this population? Are there neuroimaging techniques that can more accurately detect IPV-related TBIs? 

Deb York is a board certified Psychiatric-Mental Health Nurse Practitioner practicing in Colorado Springs, CO.  She completed her research certification as a Certified Clinical Research Associate at the Association of Clinical Research Professionals. Deb has a clinical focus in endocrine psychiatry for the treatment of a variety of psychiatric illnesses with specialized expertise in treatments for mood disorders involving menopause, andropause, PMS, PMDD and post-partum depression. 

Her research focuses on conducting clinical trials to identify and evaluate novel psychopharmacological and neuroradiological interventions for traumatic brain injury, mood disorders, and pediatric psychiatric illnesses. Additionally, Deb is certified in Bioidentical Hormone Replacement Therapy through the Academy for Preventive and Innovative Medicine by WorldLink Medical. Deb has over 25 years in the clinical trials industry conducting clinical research in pharmaceuticals & biologics, with a specialty in Women’s Health, CNS & psychiatric clinical trials.

Deb completed her Bachelor of Science in Nursing at the University of Missouri-St. Louis Barnes College of Nursing-Washington University.  She completed her Master’s Degree at the University of Cincinnati in Nurse Midwifery and her Post-Master’s Certification from the University of Cincinnati in Psychiatry-Mental Health. Additionally, Deb is an Adjunct Professor at the College of Nursing at the University of Cincinnati and Director of Clinical Research at Mountain Mind.  

In this episode, we interview Dr. Donna Wilcock, about her cutting-edge research on the role of inflammation, vascular impairment, and cerebrovascular disease on Alzheimer's disease!

Dr. Donna Wilcock is a Professor of Physiology at the University of Kentucky and the Sanders-Brown Center on Aging.

In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl on best practices for switching antipsychotics.

Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-Switch

Learning Objectives: After completing this educational activity, you should be better able to:

• Understand the relevance of receptor binding properties and pharmacokinetic profiles when switching antipsychotics
• Follow evidence-based guidelines when switching antipsychotics

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. 

Credit Types. The following are being offered for this activity:

• Nurse Practitioner (ANCC): contact hours
• Pharmacy (ACPE): knowledge-based contact hours  
• Physician (ACCME): AMA PRA Category 1 Credits ™
• Physician Assistant (AAPA): Category 1 CME credits
• Psychology (APA): CE credits
• Social Work (ASWB-ACE): ACE CE credits
• Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships, which were then mitigated prior to the activity being presented.

Interviewer

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA

Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva

Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

Interviewee

Stephen M. Stahl, MD, PhD, DSc (Hon.) 

Clinical Professor, Department of Psychiatry and Neuroscience, University of California, Riverside School of Medicine, Riverside, CA

Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA

Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK

Director of Psychopharmacology Services, California Department of State Hospitals, Sacramento, CA

Grant/Research: Acadia, Avanir, Braeburn, Intra-Cellular, Ironshore, Lilly, Neurocrine, Otsuka, Shire, Sunovion

Consultant/Advisor: AbbVie, Acadia, Alkermes, Allergan, Arbor, Axovant, Axsome, Celgene, ClearView, Concert, EMD Serono, Eisai, Ferring, Impel, Intra-Cellular, Ironshore, Janssen, Karuna, Lilly, Lundbeck, Merck, Otsuka, Pfizer, Relmada, Sage, Servier, Shire, Sunovion, Takeda, Taliaz, Teva, Tonix, Tris, Vifor

Speakers Bureau: Acadia, Lundbeck, Otsuka, Perrigo, Servier, Sunovion, Takeda, Teva, Vertex

Board Member: Genomind

Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and implicit bias can be found in this downloadable handout.

Support: This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies.

Released: January 26, 2022          CE credit expires: January 26, 2025

What types of psychotherapies are typically used in conjunction with these dissociative agents? How does psilocybin differ from ketamine for the treatment of mental health conditions? What are the risks, if any associated with this type of therapeutic approach? In Part I of this special series, the PsychopharmaStahlogy Show Dr. Andrew Cutler asks Dr. Stephen Stahl these questions, and so much more!

Don’t miss Part II and Part III of this interview.  With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month.

The first theme is on psychedelic assisted psychotherapy as a novel approach to the treatment of psychiatric disorders. Episodes to be released under this theme include:

Part I: Now You See It, Now You Don’t: The Power of Psychedelic-Assisted Psychotherapy

Part II: Forgetting to Be Addicted: Altering Compulsivity in the Addiction Process

Part III: Forgetting Your PTSD: Using Reconsolidation to Forget Traumatic Memories

Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this episode, Dr. Hu addresses important questions on her two presentations at Synapse. Join her, as she answers questions on postpartum depression and psychosis. Next, she addresses the most pressing questions on suicide risk and prevention. 

In this exciting debate from this year's NEI Synapse, Dr. Stephen Stahl and Dr. Roger McIntyre discuss whether the DSM-5 accurately captures criteria for different psychiatric disorders, such as Depression with Mixed Features. Who will win this one?

How did Fountain House come to be? What is the history behind it? What does it mean to be a Fountain House member? In this fascinating podcast, we hear from three experts who work with Fountain House to reduce stigma for people with serious mental illness, improve education, foster a community and provide resources for members of Fountain House to thrive and live fulfilling lives.

Fountain House is a national mental health nonprofit fighting to improve health, increase opportunity, and end social and economic isolation for people impacted by mental illness. Drawing on more than 200 community-based social rehabilitative programs inspired by Fountain House and known as clubhouses - to reflect an insistence on belonging and acceptance - in nearly 40 states and with more than 60,000 members, they are leading a national movement for the dignity and rights of people with serious mental illness.

Jeanie Tse, MD is the Senior Medical Director at Fountain House and an Associate Professor of Psychiatry at the NYU School of Medicine. She brings to Fountain House her expertise in integrated health care for people with serious mental illnesses, developed in the course of her work as the former Chief Medical Officer at the Institute for Community Living. She has a special interest in disrupting the impact of trauma on health outcomes, with an overarching aim to “bridge the gap” between academic psychiatry and the clinical challenges of under-resourced communities.

 Francesca Pernice, PhD is an associate professor in Educational Psychology and Director of Counseling Psychology at Wayne University's College of Education. Her areas of expertise include social and interpersonal relationships, clubhouse community recovery programs, recovery from serious mental illness, and research in mental health, and program evaluation. She instructs graduate courses in the area of adult psychopathology, ethics, and educational psychology. She serves as advisor for PhD students in the School Psychology PhD Concentration and Learning and Instructional Sciences PhD concentration within the department of Educational Psychology. Her areas of expertise include family psychoeducation about serious mental illness, and research of psychiatric rehabilitation programs known as Fountain House Clubhouses.

Cyrus Daniel Napolitano is a member of Fountain House who has served on their Board of Directors, the Council, a think-tank that focuses on innovation, training, education, research, public policy, advocacy, and technology. He is currently Co-Director of the Clubhouse New York Coalition that represents 14 clubhouses in NYC and in New Jersey. He is also working to foster the development of community-based mental health programs in low- to middle-income countries. 

Fountain House website: https://www.fountainhouse.org/

In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl on creativity in bipolar disorder.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: The Lightning in the Storm: Creativity in Bipolar Disorder

Part 2: Nikola Tesla’s Evil Twins: Genius and Madness with Marko Perko

Part 3: History of Creative Famous Individuals with Bipolar Disorder

Subscribe to the NEI Podcast, so that you don’t miss another episode!

What cultural perspectives may influence mental health stigma in the Middle East? What was your experience like creating the first transcranial magnetic stimulation (TMS) center in Kuwait? What advice do you have for clinicians who want to help reduce the stigma that surrounds mental health?

In this episode, psychiatrist Dr. Mohammad Alsuwaidan address these questions and much more.

Dr. Mohammad Alsuwaidan MD, MPH, FRCPC, DipABPN is an assistant professor of psychiatry at the University of Toronto in Canada. He is also the founder and clinical director of MindWell, a leading regional private mental health center based in Kuwait and the Chief Medical Officer of TMS NextGen a TMS training and operations management company based in Dubai.

Dr. Alsuwaidan completed his psychiatry residency, mood & anxiety disorders fellowship and medical education fellowship at the University of Toronto. He also trained in mood disorders at the Stanford University bipolar clinic and the Tufts Medical Center mood disorders clinic. He completed a Masters of Public Health (MPH) at Johns Hopkins University.

He is a Fellow of the Royal College of Physicians and Surgeons of Canada, a Diplomate of the American Board of Psychiatry and Neurology and is certified in public health by the National Board of Public Health Examiners.

He was the host for the 2022 NEI Congress, and he is widely-sought internationally as a speaker, educator and anti-stigma advocate in mental health.

In this episode, we take a look back at 2019 with Dr. Andrew Cutler, as we reflect on the most FDA approvals, exciting research findings and all the important updates in psychopharmacology that could impact your practice. 

Dr. Andrew Cutler is Chief Medical Officer (CMO) at the Neuroscience Education Institute (NEI). He has deeply rooted knowledge in clinical practice, academic experience, and emerging science in psychiatry through clinical trials. He is Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University and previously served as Courtesy Assistant Professor of Psychiatry at University of Florida. He has been the principal investigator on more than 400 psychiatric and medical clinical trials.

Stay tuned for more exciting reflections from 2019, in Part II of this episode. 

In this episode, Dr. Andrew Cutler interviews Dr. Katherine Warburton about the history of criminalization of serious mental illness, the efforts to decriminalize mental illness, and the development and success of diversion programs.

Dr. Katherine Warburton is Medical Director/Deputy Director of Clinical Operations for the California Department of State Hospitals. Prior to that, she was the Chief of Forensic Psychiatry at Napa State Hospital. She is on the volunteer clinical faculty of the UC Davis Division of Psychiatry and the Law.

With this special series, brought to you by the NEI Podcast, we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on decriminalizing mental illness.

Episodes to be released under this theme include:

Part 1: Decriminalizing Mental Illness

Part 2: Managing the Unique Challenges of Correctional Psychiatry

Part 3: The Intensive Treatment Setting and Special Cases in Forensic Psychiatry

Subscribe to the NEI Podcast so that you don’t miss another episode!

Link to “Decriminalizing Mental Illness” by Drs. Warburton and Stahl: https://www.amazon.com/Decriminalizing-Mental-Illness-Katherine-Warburton/dp/1108826954/ref=sr_1_1?crid=18XJ6RE7Y5X5M&keywords=warburton+stahl&qid=1657746214&sprefix=warburton+stahl%2Caps%2C112&sr=8-1

In this episode, Dr. Roger McIntyre addresses your most pressing questions from his presentation: Bipolar Disorder Rainbow: The Spectrum of Treatments for Depression and Mania at the 2022 NEI Synapse.

In this episode, we interview Dr. Roger McIntyre about the newest findings on inflammation and depression. 

In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre on best practices for using adjunctive treatment for major depressive disorder.

Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click https://nei.global/POD21-MDD

Learning Objectives: After completing this educational activity, you should be better able to:

• Discuss earlier identification of partial response to anti-depressants and advantages to implementing augmentation strategies sooner to improve treatment outcomes
• Increase awareness about evidence-based adjunctive treatments that are FDA-approved for depression
• Examine the pharmacological profiles of approved adjunctive atypical antipsychotic treatments in terms of how they relate to therapeutic benefits and adverse reactions

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

NEI designates this online live activity for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME/CE Credit Types. The following are being offered for this activity:

• Nursing (ANCC): 1.0 contact hour
• Pharmacy (ACPE): 1.0 application-based contact hour
• Physician (ACCME): 1.0 AMA PRA Category 1 Credit ™
• Physician Assistant (AAPA): 1.0 Category 1 CME credit
• Psychology (APA): 1.0 CE credit
• Social Work (ASWB-ACE): 1.0 ACE CE credit
• Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for 1.0 AMA PRA Category 1 Credit ™

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Potential conflicts of interest are identified and resolved prior to the activity being presented.

Interviewer

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA

Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva

Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

 Interviewee

Roger S. McIntyre, MD, FRCPC

Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada

Grant/Research: CIHR/GACD/National Natural Science Foundation of China

Consultant/Advisor: AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, Takeda

Speakers Bureau: AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, Takeda

 Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture

Support: This activity is supported by an unrestricted educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.

Released: October 21, 2021          CE credit expires: October 21, 2024

What do clinicians need to know about the pharmacokinetics of ketamine, especially when it comes to drug-drug interactions? What is the abuse potential for ketamine and for esketamine? What are some ways that clinicians can mitigate the risk of abuse? At this time, what is the consensus, in comparing the efficacy of ketamine and esketamine for treatment resistant depression? In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl on their recent publication in the American Journal of Psychiatry.

To access the article click on the link: https://pubmed.ncbi.nlm.nih.gov/33726522/

Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada.

Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade.

Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The second theme is treatment-resistant depression and suicide prevention.

Episodes to be released under this theme include:

Part 1: Treatment Resistant Depression and Suicide Prevention: Hot Off the Press Ketamine Guidelines with Dr. Roger McIntyre

Part 2: Shelter-In-Place During the Storm: Mental Health Consequences and Suicide Prevention During the COVID-19 Pandemic with Dr. Roger McIntyre

Part 3: Beyond the Storm: An Update on Suicide Prevention and The Suicide Prevention Handbook with Dr. Christine Moutier

Subscribe to the NEI Podcast, so that you don’t miss another episode!